IRCT20231117060086N1招募中2 期
Assessment of the impact of Rivaroxaban in patients with peripheral artery disease (PAD) of the lower extremities who underwent endovascular revascularization to prevent major organ and cardiovascular side effects
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients with peripheral artery disease (PAD) of the lower extremities who underwent endovascular revascularization
- •Age above 50 years
排除标准
- •Clinical need for systemic anticoagulation
研究者
相似试验
招募中
2 期
Treatment with rivaroxaban compared with warfarin in patients with acute coronary syndromeAcute coronary syndrome.Other acute ischemic heart diseasesIRCT20210614051574N9Esfahan University of Medical Sciences60
招募中
2 期
Evaluating the efficacy and safety of rivaroxaban comparing to warfarin in patients with chronic thromboembolic pulmonary hypertension (CTEPH) following endartrectomy surgeryChronic Thrombo Embolic Pulmonary Hypertension(CTEPH).Chronic Thromboembolic Pulmonary Hypertension.I27. 24IRCT20151227025726N22Shahid Beheshti University of Medical Sciences96
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of Rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) in medically ill patients.Prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill patients.MedDRA version: 18.0Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisSystem Organ Class: 100000004865EUCTR2014-000305-13-DKJanssen-Cilag International NV8,000
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of Rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) in medically ill patients.EUCTR2014-000305-13-ITJanssen-Cilag International NV8,000
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of Rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) in medically ill patients.EUCTR2014-000305-13-PTJanssen-Cilag International NV12,019